S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The Safest Option in Trades! (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The Safest Option in Trades! (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The Safest Option in Trades! (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The Safest Option in Trades! (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The Safest Option in Trades! (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The Safest Option in Trades! (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The Safest Option in Trades! (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The Safest Option in Trades! (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:QDEL

QuidelOrtho - QDEL Stock Forecast, Price & News

$71.92
-1.60 (-2.18%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$68.94
$72.65
50-Day Range
$69.86
$102.37
52-Week Range
$68.43
$180.06
Volume
649,948 shs
Average Volume
725,242 shs
Market Capitalization
$4.82 billion
P/E Ratio
3.05
Dividend Yield
N/A
Price Target
$96.50

QuidelOrtho MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
34.2% Upside
$96.50 Price Target
Short Interest
Healthy
4.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-54.57%
From $11.60 to $5.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

370th out of 1,072 stocks

Diagnostic Substances Industry

8th out of 16 stocks

QDEL stock logo

About QuidelOrtho (NASDAQ:QDEL) Stock

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Stock News Headlines

QuidelOrtho Corporation (QDEL)
QuidelOrtho Corp QDEL Stock Quote
QuidelOrtho Becomes Oversold (QDEL)
See More Headlines
Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Company Calendar

Last Earnings
8/04/2022
Today
10/05/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:QDEL
CUSIP
74838J10
Employees
1,600
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$96.50
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$80.00
Forecasted Upside/Downside
+34.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$704.23 million
Pretax Margin
47.80%

Debt

Sales & Book Value

Annual Sales
$1.70 billion
Cash Flow
$18.78 per share
Book Value
$46.30 per share

Miscellaneous

Free Float
65,145,000
Market Cap
$4.82 billion
Optionable
Optionable
Beta
0.18

Social Links


Key Executives

  • Mr. Douglas C. BryantMr. Douglas C. Bryant (Age 64)
    Chairman & CEO
    Comp: $1.41M
  • Mr. Robert J. Bujarski J.D. (Age 53)
    Pres & COO
    Comp: $770.62k
  • Ms. Michelle A. Hodges (Age 62)
    Gen. Counsel
    Comp: $620.61k
  • Dr. Werner Kroll Ph.D. (Age 65)
    Sr. VP of R&D
    Comp: $758.22k
  • Mr. Joseph M. Busky CPA (Age 54)
    Chief Financial Officer
  • Ruben Argueta
    Director of Investor Relations
  • Mr. Michael S. Iskra (Age 52)
    Chief Commercial Officer
  • Phillip S. Askim
    VP, Associate Gen. Counsel & Sec.
  • Dr. Johannes Kehle
    Pres of AnDiaTec Division
  • Mr. Rhys de Callier
    VP of Strategy & Portfolio Management













QDEL Stock - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 1 sell rating, 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings
or view top-rated stocks.

What is QuidelOrtho's stock price forecast for 2022?

4 Wall Street research analysts have issued 1-year price objectives for QuidelOrtho's stock. Their QDEL share price forecasts range from $80.00 to $130.00. On average, they anticipate the company's share price to reach $96.50 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price.
View analysts price targets for QDEL
or view top-rated stocks among Wall Street analysts.

How have QDEL shares performed in 2022?

QuidelOrtho's stock was trading at $134.99 at the beginning of 2022. Since then, QDEL stock has decreased by 46.7% and is now trading at $71.92.
View the best growth stocks for 2022 here
.

When is QuidelOrtho's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our QDEL earnings forecast
.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) issued its quarterly earnings results on Thursday, August, 4th. The company reported $2.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.56 by $1.45. The company earned $613.40 million during the quarter, compared to analyst estimates of $572.53 million. QuidelOrtho had a trailing twelve-month return on equity of 42.55% and a net margin of 36.43%.

What guidance has QuidelOrtho issued on next quarter's earnings?

QuidelOrtho updated its FY 2022 earnings guidance on Friday, September, 2nd. The company provided earnings per share guidance of $11.80-$12.75 for the period. The company issued revenue guidance of $3.78 billion-$3.91 billion, compared to the consensus revenue estimate of $2.83 billion.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?

47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

What is QuidelOrtho's stock symbol?

QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL."

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is QuidelOrtho's stock price today?

One share of QDEL stock can currently be purchased for approximately $71.92.

How much money does QuidelOrtho make?

QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $4.82 billion and generates $1.70 billion in revenue each year. The company earns $704.23 million in net income (profit) each year or $23.60 on an earnings per share basis.

How many employees does QuidelOrtho have?

The company employs 1,600 workers across the globe.

How can I contact QuidelOrtho?

QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (858) 552-1100, via email at rargueta@quidel.com, or via fax at 858-453-4338.

This page (NASDAQ:QDEL) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.